Novavax Inc. (NASDAQ: NVAX) is 3407.54% higher on its value in year-to-date trading and has touched a low of $3.54 and a high of $151.20 in the current 52-week trading range. The NVAX stock was last observed hovering at around $133.93 in the last trading session, with the day’s gains setting it 5.67% off its average median price target of $132.00 for the next 12 months. It is also 9.94% off the consensus price target high of $155.00 offered by 5 analysts, but current levels are -32.95% lower than the price target low of $105.00 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $139.60, the stock is 29.03% and 87.00% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.99 million and changing 4.23% at the moment leaves the stock 447.32% off its SMA200. NVAX registered 3184.71% gain for a year compared to 6-month gain of 1542.35%. The firm has a 50-day simple moving average (SMA 50) of $87.32 and a 200-day simple moving average (SMA200) of $35.26.
The stock witnessed a 67.11% loss in the last 1 month and extending the period to 3 months gives it a 564.45%, and is 0.99% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.79% over the week and 11.68% over the month.
Novavax Inc. (NVAX) has around 165 employees, a market worth around $8.43B and $18.10M in sales. Fwd P/E is 7.39. Distance from 52-week low is 3843.50% and -7.67% from its 52-week high.
Novavax Inc. (NVAX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Novavax Inc. (NVAX) is a “Overweight”. 5 analysts offering their recommendations for the stock have an average rating of 2.50, where 2 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Novavax Inc. is expected to release its quarterly report on 08/11/2020 and quarterly earnings per share for the current quarter are estimated at -$0.41 with sales reaching $39.58M over the same period.The EPS is expected to grow by 44.90% this year, but quarterly earnings will post 6,089.00% year-over-year. Quarterly sales are estimated to grow 1,193.50% in year-over-year returns.
Novavax Inc. (NVAX) Top Institutional Holders
130 institutions hold shares in Novavax Inc. (NVAX), with 210.2k shares held by insiders accounting for 0.36% while institutional investors hold 13.94% of the company’s shares. The shares outstanding are 58.69M, and float is at 54.38M with Short Float at 14.95%. Institutions hold 13.89% of the Float.
Novavax Inc. (NVAX) Insider Activity
A total of 16 insider transactions have happened at Novavax Inc. (NVAX) in the last six months, with sales accounting for 7 and purchases happening 9 times. The most recent transaction is an insider sale by Glenn Gregory M, the company’s President, R&D. SEC filings show that Glenn Gregory M sold 16,749 shares of the company’s common stock on Jun 18 at a price of $59.53 per share for a total of $1.0 million. Following the sale, the insider now owns 1839.0 shares.
Novavax Inc. disclosed in a document filed with the SEC on Jun 03 that YOUNG JAMES F (Director) bought a total of 1,500 shares of the company’s common stock. The trade occurred on Jun 03 and was made at $48.83 per share for $73245.0. Following the transaction, the insider now directly holds 1500.0 shares of the NVAX stock.
Still, SEC filings show that on May 18, Herrmann John A III (SVP, General Counsel) disposed off 12,961 shares at an average price of $49.44 for $0.64 million. The insider now directly holds 275 shares of Novavax Inc. (NVAX).